News

FDA Grants PLX-100 Orphan Drug Designation to Treat Batten Disease

Polaryx Therapeutics’ investigative drug PLX-100 has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neuronal ceroid lipofuscinosis (NCL), also known as Batten disease. This follows the previous announcement of ODD status granted to PLX-200, another drug being tested…

Batten Organization’s Director Says Scientists Zeroing In on Treatments

WASHINGTON — As the Batten Disease Support and Research Association celebrates its 30th anniversary, the group’s executive director says scientists are edging ever closer to treatments for the incurable genetic disorder. Margie Frazier said the organization she’s headed for five years is the only one that represents all 14 forms…